another low, page-6

Interesting issue you raise Esc.

I wonder how PC's bias could manifest itself?

As part of the review RP might decide to cancel and financially write off one of our antibacterial programs that was PC's legacy purchase back in 2009? PC might not be impressed with that.

Closing down the Australian and Oxford locations might also cause some emotional disturbance at board level?

But these are minor issues...I'm more interested in how RP sees us funding our major programs to commercialisation... I lack, how do you say, that visibility from where I'm sitting...